News
President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price ...
Axios on MSN6d
Vinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics ...
Not Vinay Prasad. The new top regulator of vaccines and gene therapies at the Food and Drug Administration has never shied ...
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...
Previously, she was executive editor of Chemical & Engineering News. The controversial appointment of oncologist Vinay Prasad — an outspoken critic of the pharmaceutical industry and US health ...
Vinay Prasad, a skeptic of mainstream medicine, is now a top FDA official. Change is coming for some drugmakers, one way or ...
MedPage Today on MSN9d
Vinay Prasad, Critic of COVID Measures, Picked as FDA's Top Vaccine OfficialVinay Prasad, MD, MPH, a frequent critic of the FDA and COVID-19 lockdowns and vaccination policies, will be the next ...
HealthDay on MSN2d
Dr Vinay Prasad to Head FDA Vaccine, Biologics DivisionThe FDA has chosen Dr Vinay Prasad, a professor at UCSF, to lead its Center for Biologics Evaluation and Research.
(Reuters) -The U.S. Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized FDA ...
Vinay Prasad will be the next director of the FDA's Center for Biologics Evaluation and Research, after Peter Marks was forced out.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback